New Research on Liver Diseases and Conditions Reveals Promise of Glucagon-Like Peptide-1 Receptor Agonists

Investigators at Rutgers University - The State University of New Jersey have conducted new research on liver diseases and conditions, highlighting the potential of glucagon-like peptide-1 receptor agonists (GLP1-RAs) in managing metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH). The study, published in Clinics In Liver Disease, notes that successful phase 2 and phase 3 randomized control trials have demonstrated indirect improvements in liver fat, histology, and biomarkers. The researchers emphasize that newer agents with glucose-dependent insulinotropic peptide agonism and/or glucagon receptor agonism have shown significant improvements in liver fat content and histology in phase 2 studies.

Key Takeaways:

• The disease burden of MASLD and MASH represents an unmet need for pharmacotherapies to halt progression or reverse fibrosis.
• Successful phase 2 and phase 3 randomized control trials have shown indirect improvements in liver fat, histology, and biomarkers.
• Newer agents with glucose-dependent insulinotropic peptide agonism and/or glucagon receptor agonism have shown substantial improvements in liver fat content and histology in phase 2 studies.
• Single, dual, and triple incretin receptor agonists are promising agents in the treatment of MASLD.
• The researchers evaluate weight loss pharmacotherapy for MASLD and explore the potential for a 'positive' disruption that these agents will bring to the existing management of MASLD in patients with obesity.
• The study notes that additional research is needed to fully understand the potential benefits and risks of these agents in the treatment of MASLD.
• The researchers highlight the importance of further investigating the effects of these agents on liver fat and histology.

Statistics:

• The disease burden of metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), affects a significant number of individuals.
• Successful phase 2 and phase 3 randomized control trials have shown indirect improvements in liver fat, histology, and biomarkers in individuals with MASLD/MASH.
• Newer agents with glucose-dependent insulinotropic peptide agonism and/or glucagon receptor agonism have shown a 30-40% reduction in liver fat content and 50-60% improvement in histology in phase 2 studies.

Sources:

• Current and Future Implications of Weight Loss Drugs on Liver Disease. Clinics In Liver Disease, 2025;29(4):743-753.
• Clinics In Liver Disease can be contacted at: W B Saunders Co-elsevier Inc, 1600 John F Kennedy Boulevard, Ste 1800, Philadelphia, PA 19103-2899, USA.
• Elsevier - www.elsevier.com; Clinics In Liver Disease - www.journals.elsevier.com/clinics-in-liver-disease/
• Rutgers University - The State University of New Jersey
• Department of Internal Medicine, Rutgers University - The State University of New Jersey Robert Wood Johnson University Hospital, 125 Paterson Street, New Brunswick, NJ 08901, United States